Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

This release includes forward-looking statements concerning the company's plans to initiate Phase III trials of the subcutaneous administration of GAMMAGARD LIQUID alone and with Enhanze Technology and expectations regarding the availability of the results related thereto. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: timely submission and approval of anticipated regulatory filings; the ability of the company to enroll a sufficient number of qualified participants in the proposed Phase III trials; the ability of the company to otherwise successfully initiate the Phase III trials; the ability of the company to complete the Phase III trials or any of them on a timely basis; and other risks discussed in the company's filings with the Securities and Exchange Commission (SEC) that could cause actual results to differ materially from those in the forward-looking statements. The company's SEC filings are available on its website. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changes assumptions or otherwise, and all forward- looking statements speak only as of the time when made. Actual results or experience could differ materially from the expectations contained in the forward-looking statements.

GAMMAGARD LIQUID and KIOVIG are trademarks of Baxter Hea
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... March 5, 2012 Medical Care Technologies Inc. ... Special Meeting of Shareholders of the Company,s common stock held ... for lack of quorum. The adjourned Special Meeting will occur ... to provide time for the shareholders to ensure that their ...
... Wash., March 5, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... product information and "where to buy" details for their ... available retailers can be found on www.scolr.com ... page can be reached from the home page or ...
Cached Medicine Technology:Medical Care Technologies Inc. Announces Adjournment of Special Meeting 2Medical Care Technologies Inc. Announces Adjournment of Special Meeting 3SCOLR Pharma, Inc. Provides Product Information on Website 2
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A new, injectable weight-loss ... Drug Administration. The agency on Tuesday approved Saxenda ... who are overweight and have at least one weight-related ... diabetes or high cholesterol. Patients taking the drug, ... diet and exercise regularly, the FDA noted. "Obesity ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... from the American Diabetes Association (ADA) call for giving the ... to help prevent heart disease. These new standards bring ... and American Heart Association, which also recommend giving low- or ... including people with diabetes. "We agree that the decision ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... Aug. 13 As the debate over health care reform heats up, ... district has been, well, blunted. , , The billboard ... Blunt has taken $556,682 in contributions from the insurance industry. Is that ... , USAction and its Missouri affiliate, Missouri Progressive Vote Coalition, ...
... sexual assault and seeking help is difficult for anyone, but ... (LGBTQ) the thought of reporting a crime may well be ... a study in Oregon. The study, appearing in the ... found that 94 percent of respondents -- most of them ...
... , , , ... care industry moves from paper-based to electronic record-keeping, protecting confidential ... issue, Verizon is unveiling two new capabilities designed to help ... clinics, physicians, insurers and patients. , , ...
... , TORONTO, Aug. 13 /PRNewswire-FirstCall/ - Patheon Inc. (TSX: ... services to the global pharmaceutical industry, announced today that ... on Monday, September 14, 2009. , In conjunction with ... financial analysts on Monday, September 14, 2009 at 10:00 ...
... TOSU, SAGA, Japan, Aug. 13 Hisamitsu Pharmaceutical Co., Inc. ... announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust ... p.m., New York City time, on August 12, 2009, with respect ... NOVN ). , , ...
... Medical Research Council (MRC) scientists have made an important advance ... to die. The work may help scientists to eventually develop ... occur when cell death goes wrong. The research, published ... 14 August 2009) was carried out by a team of ...
Cached Medicine News:Health News:Blunted by Roy Blunt: The Billboard the Congressman Doesn't Want You to See 2Health News:Little safe haven for sexually assaulted LGBTQ victims 2Health News:Little safe haven for sexually assaulted LGBTQ victims 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 4Health News:Patheon Announces Date of Third Quarter 2009 Financial Results Release, Conference Call and Webcast 2Health News:Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals 2Health News:MRC scientists advance understanding of cell death 2
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
10L...
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Medicine Products: